Corium International Inc (CORI) Expected to Announce Earnings of -$0.33 Per Share
Wall Street brokerages forecast that Corium International Inc (NASDAQ:CORI) will post earnings per share (EPS) of ($0.33) for the current quarter, Zacks reports. Two analysts have provided estimates for Corium International’s earnings, with estimates ranging from ($0.36) to ($0.29). Corium International reported earnings per share of ($0.36) during the same quarter last year, which would indicate a positive year over year growth rate of 8.3%. The firm is scheduled to report its next quarterly earnings results on Thursday, November 15th.
According to Zacks, analysts expect that Corium International will report full year earnings of ($1.53) per share for the current financial year, with EPS estimates ranging from ($1.56) to ($1.50). For the next financial year, analysts forecast that the company will report earnings of ($1.42) per share, with EPS estimates ranging from ($1.73) to ($1.10). Zacks’ EPS averages are an average based on a survey of research analysts that cover Corium International.
Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.04. The business had revenue of $7.67 million during the quarter, compared to the consensus estimate of $6.72 million. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%.
NASDAQ:CORI traded up $0.36 during mid-day trading on Tuesday, reaching $9.40. The stock had a trading volume of 299,421 shares, compared to its average volume of 172,110. The company has a current ratio of 7.61, a quick ratio of 7.47 and a debt-to-equity ratio of 2.83. Corium International has a 1-year low of $7.17 and a 1-year high of $13.93.
In other Corium International news, VP Parminder Singh sold 3,133 shares of the firm’s stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $9.01, for a total value of $28,228.33. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Peter D. Staple sold 76,341 shares of the firm’s stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $8.81, for a total transaction of $672,564.21. Following the completion of the transaction, the chief executive officer now directly owns 362,316 shares in the company, valued at approximately $3,192,003.96. The disclosure for this sale can be found here. Insiders sold 119,965 shares of company stock worth $1,060,275 in the last three months. 30.80% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of CORI. Franklin Resources Inc. raised its holdings in shares of Corium International by 115.3% during the first quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock valued at $23,618,000 after buying an additional 1,102,910 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Corium International by 17.8% during the second quarter. BlackRock Inc. now owns 2,215,762 shares of the biopharmaceutical company’s stock valued at $17,748,000 after buying an additional 335,257 shares during the last quarter. Royce & Associates LP raised its holdings in shares of Corium International by 99.2% during the second quarter. Royce & Associates LP now owns 502,564 shares of the biopharmaceutical company’s stock valued at $4,026,000 after buying an additional 250,300 shares during the last quarter. Candriam Luxembourg S.C.A. raised its holdings in shares of Corium International by 127.9% during the first quarter. Candriam Luxembourg S.C.A. now owns 196,000 shares of the biopharmaceutical company’s stock valued at $2,248,000 after buying an additional 110,000 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Corium International by 1,746.7% during the first quarter. JPMorgan Chase & Co. now owns 96,935 shares of the biopharmaceutical company’s stock valued at $1,112,000 after buying an additional 91,686 shares during the last quarter.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Featured Story: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.